全文获取类型
收费全文 | 64669篇 |
免费 | 5808篇 |
国内免费 | 2662篇 |
专业分类
耳鼻咽喉 | 691篇 |
儿科学 | 1681篇 |
妇产科学 | 1149篇 |
基础医学 | 6440篇 |
口腔科学 | 1199篇 |
临床医学 | 5897篇 |
内科学 | 6131篇 |
皮肤病学 | 805篇 |
神经病学 | 2153篇 |
特种医学 | 3425篇 |
外国民族医学 | 53篇 |
外科学 | 7898篇 |
综合类 | 10843篇 |
现状与发展 | 19篇 |
预防医学 | 1876篇 |
眼科学 | 610篇 |
药学 | 5673篇 |
46篇 | |
中国医学 | 2241篇 |
肿瘤学 | 14309篇 |
出版年
2024年 | 149篇 |
2023年 | 950篇 |
2022年 | 2143篇 |
2021年 | 2823篇 |
2020年 | 2259篇 |
2019年 | 2074篇 |
2018年 | 1940篇 |
2017年 | 2172篇 |
2016年 | 2429篇 |
2015年 | 2576篇 |
2014年 | 3902篇 |
2013年 | 4146篇 |
2012年 | 3610篇 |
2011年 | 3971篇 |
2010年 | 3195篇 |
2009年 | 3209篇 |
2008年 | 3223篇 |
2007年 | 3495篇 |
2006年 | 3131篇 |
2005年 | 2814篇 |
2004年 | 2426篇 |
2003年 | 2044篇 |
2002年 | 1909篇 |
2001年 | 1705篇 |
2000年 | 1406篇 |
1999年 | 1265篇 |
1998年 | 1071篇 |
1997年 | 1001篇 |
1996年 | 865篇 |
1995年 | 778篇 |
1994年 | 662篇 |
1993年 | 524篇 |
1992年 | 443篇 |
1991年 | 379篇 |
1990年 | 305篇 |
1989年 | 274篇 |
1988年 | 279篇 |
1987年 | 224篇 |
1986年 | 175篇 |
1985年 | 215篇 |
1984年 | 191篇 |
1983年 | 125篇 |
1982年 | 156篇 |
1981年 | 132篇 |
1980年 | 97篇 |
1979年 | 90篇 |
1978年 | 67篇 |
1977年 | 44篇 |
1976年 | 38篇 |
1975年 | 15篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
目的 探讨肝细胞癌(HCC)合并胆管癌栓患者术中癌栓的处理方式和术后恢复过程。方法 对1995年1月-2002年12月手术治疗的27例HCC合并胆管癌栓情况进行回顾性总结和分析。结果 只有59.3%(16/27)患者行肝切除、胆管取癌栓及胆管引流术。全组术后并发症发生率为55.6%(15/27),术后30d病死率为22.2%(6/27)。结论 HCC合并胆管癌栓的预后差,早期诊断和外科手术治疗是改善此病预后的关键。 相似文献
92.
目的研究新型脑肿瘤显像剂:11^C-蛋氨酸(11^C-MET)的体内生物学分布,探讨11^C—MET的临床显像方法及其在脑肿瘤显像中的应用.方法测定11^C—MET在小鼠体内的分布,对健康志愿者和病理证实胶质瘤患者进行PET脑显像.结果小鼠体内分布实验和脑PET显像发现,11^C—MET在血液中清除较慢,在肿瘤内有较长的滞留时问,平台期位于30—45min之间,延迟相对有利于脑瘤的显像,其余放射性主要集中在消化系统.结论11^C—MDT有较高的肿瘤/脑比值,是理想的脑肿瘤显像剂. 相似文献
93.
骨外型牙源性钙化上皮瘤1例报告 总被引:2,自引:0,他引:2
牙源性钙化上皮瘤是一种良性肿瘤,也称Pindborg瘤,可分为骨内型和骨外型2种,主要发生于颌骨内,偶见于颌骨外。本文报告1例发生于口底的牙源性钙化上皮瘤,其临床症状与口底皮样囊肿相似.术后经组织病理学确诊,主要组织病理学特征是嗜酸性环状钙化团块。因其具有局部侵袭性,为避免复发,提倡完整切除肿物。 相似文献
94.
[目的]应用固体滴定技术监测羟基磷灰石(Hydroxyaptite,HA)的溶解平衡过程,观察组织液生理浓度CO2对羟基磷灰石溶解度的影响.[方法]在恒温水浴系统中以HA为固体滴定物.测试液为KCl溶液(0.1 mol/L),并引入恒定分压的CO2(占空气体积比为3.5%±0.1%).半导体二极管激光为发射光源,散射光源探测器用于监测HA的溶解平衡过程并判断超越溶解平衡点所出现的沉淀(合共17次滴定终点).固体滴定总量用于代表溶解度等温线上的数据点.[结果]引入恒定分压CO2后测定的HA在KCl溶液中的溶解度高于其在KCl溶液中所得50倍以上.[结论]固体滴定技术利于监测HA的溶解平衡过程.溶液体系中CO2增加HA的溶解度.推测该现象与CO2-3形成的复合物密切相关. 相似文献
95.
目的:观察密盖息(鲑鱼降钙素)的治疗骨转移瘤疼痛和血清钙的临床疗效。方法:单用组用密盖息100IU,肌肉注射,每日2次,共7d。联合化疗组化疗后加密盖息100IU肌肉注射,每日2次,每次7d。治疗结束进行疗效评价。结果:单用组骨痛完全缓解66.7%(12/18)。联合化疗组骨痛完全缓解率87.1%(27/31)。单用组血钙降至正常,占77.8%(14/18),联合化疗组血钙完全降至正常占100%(31/31)。副作用是暂时性的心动过速、皮肤潮红、头晕、恶心呕吐,无需特殊处理,自行缓解。结论:密盖息治疗骨转移瘤有止痛、降低血钙作用良好,副作用小,可以在临床上安全使用。 相似文献
96.
Kimberly A. Varker Edward W. Martin Dori Klemanski Bryan Palmer Manisha H. Shah Mark Bloomston 《Journal of gastrointestinal surgery》2007,11(12):1680-1685
Background
Transarterial chemoemobolization (TACE) is commonly used to treat metastatic carcinoid tumors; however, the management of
progressive disease is less clear. We sought to determine if patients with disease progression after TACE would benefit from
repeat TACE.
Methods
The records of 27 patients undergoing repeat TACE for radiologic or symptomatic progression after TACE for metastatic carcinoid
were reviewed and compared to 122 undergoing first TACE. Overall and progression-free survivals were estimated by the Kaplan–Meier
method.
Results
Mean disease-free interval after first TACE was 11.8 months. Radiologic response was observed in 61% compared to 82% after
first TACE (p = 0.058); hormone response in 64% compared to 80% (p = 0.159); and symptomatic response in 77% compared to 92% (p = 0.053). The complication rate after repeat TACE was lower than after first TACE (p = 0.03). Median overall survival was similar after repeat (28.1 months) and first TACE (33.3 months) (p = 0.53). Progression-free survival was shorter after repeat TACE but not significantly so. No factor examined could predict
survival after repeat TACE.
Conclusion
Repeat TACE for patients with hepatic carcinoid metastases failing first TACE or having evidence of disease progression is
safe and offers a viable treatment option.
Presented at the 48th Annual Meeting of The Society for Surgery of the Alimentary Tract, Washington, DC, May, 2007. 相似文献
97.
目的探讨经乙状窦后入路显微手术治疗桥小脑角占位性病变引起的继发性三叉神经痛的疗效。方法回顾分析我院2000年10月~2006年7月37例继发性三叉神经痛的临床资料,其中胆脂瘤18例,脑膜瘤8例,听神经瘤6例,三叉神经鞘瘤5例,均经乙状窦后入路显微手术切除肿瘤。结果肿瘤全切23例,次全切除10例,部分切除4例。35例疼痛症状消失(32例立即消失,3例术后2个月消失),随访3个月~5年无复发;2例无效。发生暂时性面瘫6例,面部麻木6例,无颅内感染及脑脊液漏。结论经乙状窦后入路显微手术是治疗继发性三叉神经痛安全有效的方法。 相似文献
98.
Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour.
Anastasios Matzavinos Mark A J Chaplain Vladimir A Kuznetsov 《Mathematical medicine and biology》2004,21(1):1-34
In this paper a mathematical model describing the growth of a solid tumour in the presence of an immune system response is presented. In particular, attention is focused upon the attack of tumour cells by so-called tumour-infiltrating cytotoxic lymphocytes (TICLs), in a small, multicellular tumour, without necrosis and at some stage prior to (tumour-induced) angiogenesis. At this stage the immune cells and the tumour cells are considered to be in a state of dynamic equilibrium--cancer dormancy--a phenomenon which has been observed in primary tumours, micrometastases and residual disease after ablation of the primary tumour. Nonetheless, the precise biochemical and cellular mechanisms by which TICLs control cancer dormancy are still poorly understood from a biological and immunological point of view. Therefore we focus on the analysis of the spatio-temporal dynamics of tumour cells, immune cells and chemokines in an immunogenic tumour. The lymphocytes are assumed to migrate into the growing solid tumour and interact with the tumour cells in such a way that lymphocyte-tumour cell complexes are formed. These complexes result in either the death of the tumour cells (the normal situation) or the inactivation (sometimes even the death) of the lymphocytes. The migration of the TICLs is determined by a combination of random motility and chemotaxis in response to the presence of chemokines. The resulting system of four nonlinear partial differential equations (TICLs, tumour cells, complexes and chemokines) is analysed and numerical simulations are presented. We consider two different tumour geometries--multi-layered cell growth and multi-cellular spheroid growth. The numerical simulations demonstrate the existence of cell distributions that are quasi-stationary in time and heterogeneous in space. A linear stability analysis of the underlying (spatially homogeneous) ordinary differential equation (ODE) kinetics coupled with a numerical investigation of the ODE system reveals the existence of a stable limit cycle. This is verified further when a subsequent bifurcation analysis is undertaken using a numerical continuation package. These results then explain the complex heterogeneous spatio-temporal dynamics observed in the partial differential equation (PDE) system. Our approach may lead to a deeper understanding of the phenomenon of cancer dormancy and may be helpful in the future development of more effective anti-cancer vaccines. 相似文献
99.
100.
Ian F. Dunn Pankaj K. Agarwalla Alexander M. Papanastassiou William E. Butler Edward R. Smith 《Child's nervous system》2007,23(10):1191-1194
Objective Approximately 10% of patients with neurofibromatosis I (NFI) patients will have central nervous system (CNS) tumors. The most
common of these are hypothalamic–optic gliomas, followed by brainstem and cerebellar pilocytic astrocytomas. While isolated
pilocytic astrocytomas in NFI are well described, the appearance of multiple pilocytic astrocytomas in an individual patient
is less common. The most frequent combination in NFI patients with more than one pilocytic astrocytoma is optic tract/hypothalamic
and brainstem. Other combinations are exceedingly rare; multiple pilocytic astrocytomas have only been reported once in the
cerebral hemispheres in a patient with NFI. This report presents the first documented case, to our knowledge, of multiple
pilocytic astrocytomas in the cerebellum of a patient with NF1.
Methods Case report.
Conclusion The finding of multiple cerebellar pilocytic astrocytomas in a patient with NF1 is important because it expands the spectrum
of presentations for patients with NF1 and also highlights specific diagnostic and therapeutic challenges faced by the treating
physicians. The genetic and molecular basis of NF1 is reviewed. Strategies of diagnosis and treatment outlined here are relevant
to both patients with NF1 and all patients with multiple posterior fossa tumors. 相似文献